In 2023, Novo paid 62% of its gross sales back in rebates across its sales
[1] Alternative Weight Management Options for Hashimoto's Patients For patients with Hashimoto's thyroiditis who are not suitable candidates for Wegovy, or who prefer alternative approaches, several evidence-based weight management strategies exist

article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)

Wegovy (semaglutide) oral tablet is indicated for weight loss and long-term weight maintenance, as well as to reduce the risk of major adverse cardiovascular events such as death, heart attack, or stroke in adults with established cardiovascular disease and either obesity or overweight